

DAFTAR PUSTAKA

- (1) Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global Cancer Statistics. *CA Cancer J Clin* **2011**, *61* (2), 69–90. <https://doi.org/10.3322/caac.20107>.
- (2) Marisa, D.; Hayatie, L.; Juliati, S.; Suhartono, E.; Komari, N. Molecular Docking of Phytosterols in *Stenochlaena Palustris* as Anti-Breast Cancer. *Acta Biochimica Indonesiana* **2021**, *4* (2), 59. <https://doi.org/10.32889/actabioina.59>.
- (3) Haryanti, S.; Widiyastuti, Y. Aktivitas Sitotoksik Pada Sel MCF-7 Dari Tumbuhan Indonesia Untuk Pengobatan Tradisional Kanker Payudara. *Media Penelitian dan Pengembangan Kesehatan* **2017**, *27* (4). <https://doi.org/10.22435/mpk.v27i4.5010.247-254>.
- (4) Sriwiryajan, S.; Ninpesh, T.; Sukpondma, Y.; Nasomyon, T.; Graidist, P. Cytotoxicity Screening of Plants of Genus *Piper* in Breast Cancer Cell Lines. *Tropical Journal of Pharmaceutical Research* **2014**, *13* (6), 921–928. <https://doi.org/10.4314/tjpr.v13i6.14>.
- (5) Parmar, V. S.; Jain, S. C.; Gupta, S.; Talwar, S.; Rajwanshi, V. K.; Kumar, R.; Azim, A.; Malhotra, S.; Kumar, N.; Jain, R.; Sharma, N. K.; Tyagi, O. D.; Lawrie, S. J.; Errington, W.; Howarth, O. W.; Olsen, C. E.; Wengel, S. K. S. Polyphenols and Alkaloids from *Piper* Species. *Phytochemistry* **1998**, *49* (4), 1069–1078. [https://doi.org/https://doi.org/10.1016/S0031-9422\(98\)00208-8](https://doi.org/https://doi.org/10.1016/S0031-9422(98)00208-8).
- (6) Tawan, C.; Ipor, I. B.; Sani, H. Brief Account on the Wild *Piper* (Piperaceae) of the Crocker Range, Sabah. *ASEAN Rev Biodiv Environ Conserv* **2002**.
- (7) Rajudin, E.; Ahmad, F.; Sirat, H. M.; Arbain, D.; Aboul-Enein, H. Y. Chemical Constituents from Tiger's Betel, *Piper Porphyrophyllum* N.E.Br. (Fam. Piperaceae). *Nat Prod Res* **2010**, *24* (4), 387–390. <https://doi.org/10.1080/14786410903421826>.
- (8) Mai Efdi. Unpublish Manuscript.
- (9) Chuwa, A. H.; Sone, K.; Oda, K.; Tanikawa, M.; Kukita, A.; Kojima, M.; Oki, S.; Fukuda, T.; Takeuchi, M.; Miyasaka, A.; Kashiwama, T.; Ikeda, Y.; Nagasaka, K.; Mori-Uchino, M.; Matsumoto, Y.; Wada-Hiraike, O.; Kuramoto, H.; Kawana, K.; Osuga, Y.; Fujii, T. Kaempferol, a Natural Dietary Flavonoid, Suppresses 17 β -Estradiol-Induced Survivin Expression and Causes Apoptotic Cell Death in Endometrial Cancer. *Oncol Lett* **2018**, *16* (5), 6195–6201. <https://doi.org/10.3892/ol.2018.9340>.
- (10) Yang, J.-F.; Cao, J.-G.; Tian, L.; Liu, F. 5, 7-Dimethoxyflavone Sensitizes TRAIL-Induced Apoptosis through DR5 Upregulation in Hepatocellular Carcinoma Cells. *Cancer Chemother Pharmacol* **2012**, *69* (1), 195–206. <https://doi.org/10.1007/s00280-011-1686-9>.
- (11) Park, W.; Park, M. Y.; Song, G.; Lim, W. 5,7-Dimethoxyflavone Induces Apoptotic Cell Death in Human Endometriosis Cell Lines by Activating the Endoplasmic Reticulum Stress Pathway. *Phytotherapy Research* **2020**, *34* (9), 2275–2286. <https://doi.org/10.1002/ptr.6677>.
- (12) Grinevicius, V. M. A. S.; Andrade, K. S.; Mota, N. S. R. S.; Bretanha, L. C.; Felipe, K. B.; Ferreira, S. R. S.; Pedrosa, R. C. CDK2 and Bcl-XL Inhibitory Mechanisms by Docking Simulations and Anti-Tumor Activity from Piperine Enriched Supercritical Extract. *Food and Chemical Toxicology* **2019**, *132*. <https://doi.org/10.1016/j.fct.2019.110644>.
- (13) Siegel, R.; Naishadham, D.; Jemal, A. Cancer Statistics, 2013. *CA Cancer J Clin* **2013**, *63* (1), 11–30. <https://doi.org/https://doi.org/10.3322/caac.21166>.

- (14) Hassanpour, S. H.; Dehghani, M. Review of Cancer from Perspective of Molecular. *Journal of Cancer Research and Practice* **2017**, *4* (4), 127–129. <https://doi.org/10.1016/j.jcrpr.2017.07.001>.
- (15) Parkin, D. M. The Global Health Burden of Infection-Associated Cancers in the Year 2002. *Int J Cancer* **2006**, *118* (12), 3030–3044. <https://doi.org/https://doi.org/10.1002/ijc.21731>.
- (16) Seto, M.; Honma, K.; Nakagawa, M. Diversity of Genome Profiles in Malignant Lymphoma. *Cancer Sci* **2010**, *101* (3), 573–578. <https://doi.org/https://doi.org/10.1111/j.1349-7006.2009.01452.x>.
- (17) Cigudosa, J. C.; Parsa, N. Z.; Louie, D. C.; Filippa, D. A.; Jhanwar, S. C.; Johansson, B.; Mitelman, F.; Chaganti, R. S. K. Cytogenetic Analysis of 363 Consecutively Ascertained Diffuse Large B-Cell Lymphomas. *Genes Chromosomes Cancer* **1999**, *25* (2), 123–133. [https://doi.org/https://doi.org/10.1002/\(SICI\)1098-2264\(199906\)25:2<123::AID-GCC8>3.0.CO;2-4](https://doi.org/https://doi.org/10.1002/(SICI)1098-2264(199906)25:2<123::AID-GCC8>3.0.CO;2-4).
- (18) Shtivelman, E.; Lifshitz, B.; Gale, R. P.; Canaani, E. Fused Transcript of Abl and Bcr Genes in Chronic Myelogenous Leukaemia. *Nature* **1985**, *315* (6020), 550–554. <https://doi.org/10.1038/315550a0>.
- (19) Matlashewski, G.; Lamb, P.; Pim, D.; Peacock, J.; Crawford, L.; Benchimol, S. Isolation and Characterization of a Human P53 CDNA Clone: Expression of the Human P53 Gene. *EMBO J* **1984**, *3* (13), 3257–3262–3262. <https://doi.org/https://doi.org/10.1002/j.1460-2075.1984.tb02287.x>.
- (20) Lukong, K. E. Understanding Breast Cancer – The Long and Winding Road. *BBA Clin* **2017**, *7*, 64–77. <https://doi.org/https://doi.org/10.1016/j.bbaci.2017.01.001>.
- (21) Murawa, P.; Murawa, D.; Adamczyk, B.; Połom, K. Breast Cancer: Actual Methods of Treatment and Future Trends. *Reports of Practical Oncology & Radiotherapy* **2014**, *19* (3), 165–172. <https://doi.org/https://doi.org/10.1016/j.rpor.2013.12.003>.
- (22) Goldhirsch, A.; Winer, E. P.; Coates, A. S.; Gelber, R. D.; Piccart-Gebhart, M.; Thürlimann, B.; Senn, H. J.; Albain, K. S.; André, F.; Bergh, J.; Bonnefoi, H.; Bretel-Morales, D.; Burstein, H.; Cardoso, F.; Castiglione-Gertsch, M.; Coates, A. S.; Colleoni, M.; Costa, A.; Curigliano, G.; Davidson, N. E.; Leo, A. Di; Ejlertsen, B.; Forbes, J. F.; Gelber, R. D.; Gnant, M.; Goodwin, P.; Goss, P. E.; Harris, J. R.; Hayes, D. F.; Hudis, C. A.; Ingle, J. N.; Jassem, J.; Jiang, Z.; Karlsson, P.; Loibl, S.; Morrow, M.; Namer, M.; Osborne, C. K.; Partridge, A. H.; Penault-Llorca, F.; Perou, C. M.; Pritchard, K. I.; Rutgers, E. J. T.; Sedlmayer, F.; Semiglazov, V.; Shao, Z. M.; Smith, I.; Thürlimann, B.; Toi, M.; Tutt, A.; Untch, M.; Viale, G.; Watanabe, T.; Wilcken, N.; Winer, E. P.; Wood, W. C. Personalizing the Treatment of Women with Early Breast Cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Annals of Oncology* **2013**, *24* (9), 2206–2223. <https://doi.org/10.1093/annonc/mdt303>.
- (23) Prat, A.; Cheang, M. C. U.; Martín, M.; Parker, J. S.; Carrasco, E.; Caballero, R.; Tyldesley, S.; Gelmon, K.; Bernard, P. S.; Nielsen, T. O.; Perou, C. M. Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer. *Journal of Clinical Oncology* **2012**, *31* (2), 203–209. <https://doi.org/10.1200/JCO.2012.43.4134>.
- (24) Slamon, D.; Eiermann, W.; Robert, N.; Pienkowski, T.; Martin, M.; Press, M.; Mackey, J.; Glaspy, J.; Chan, A.; Pawlicki, M.; Pinter, T.; Valero, V.; Liu, M.-C.; Sauter, G.; von Minckwitz, G.; Visco, F.; Bee, V.; Buyse, M.; Bendahmane, B.; Tabah-Fisch, I.; Lindsay, M.-A.; Riva, A.; Crown, J. *Adjuvant Trastuzumab in HER2-Positive Breast Cancer*; 2011; Vol. 14.

- (25) D, F. W.; E, S. I.; S, R.-F. J. Triple-Negative Breast Cancer. *New England Journal of Medicine* **2024**, *363* (20), 1938–1948. <https://doi.org/10.1056/NEJMra1001389>.
- (26) Sawyers, C. Targeted Cancer Therapy. *Nature* **2004**, *432* (7015), 294–297. <https://doi.org/10.1038/nature03095>.
- (27) Shuel, S. L. Targeted Cancer Therapies. *Canadian Family Physician* **2022**, *68* (7), 515–518. <https://doi.org/10.46747/cfp.6807515>.
- (28) Leone, S.; Busonero, C.; Acconcia, F. A High Throughput Method to Study the Physiology of E2:ER α Signaling in Breast Cancer Cells. *J Cell Physiol* **2018**, *233* (5), 3713–3722. <https://doi.org/https://doi.org/10.1002/jcp.26251>.
- (29) NCBI. *ESR1 estrogen receptor 1 [Homo sapiens (human)]*. <https://www.ncbi.nlm.nih.gov/gene/2099> (accessed 2024-07-12).
- (30) Green, K. A.; Carroll, J. S. Oestrogen-Receptor-Mediated Transcription and the Influence of Co-Factors and Chromatin State. *Nat Rev Cancer* **2007**, *7* (9), 713–722. <https://doi.org/10.1038/nrc2211>.
- (31) Tian, W.; Teng, F.; Gao, J.; Gao, C.; Liu, G.; Zhang, Y.; Yu, S.; Zhang, W.; Wang, Y.; Xue, F. Estrogen and Insulin Synergistically Promote Endometrial Cancer Progression via Crosstalk between Their Receptor Signaling Pathways. *Cancer Biol Med* **2019**, *16* (1), 55. <https://doi.org/10.20892/j.issn.2095-3941.2018.0157>.
- (32) Cuesta, R.; Gritsenko, M. A.; Petyuk, V. A.; Shukla, A. K.; Tsai, C.-F.; Liu, T.; McDermott, J. E.; Holz, M. K. Phosphoproteome Analysis Reveals Estrogen-ER Pathway as a Modulator of MTOR Activity Via DEPTOR *. *Molecular & Cellular Proteomics* **2019**, *18* (8), 1607–1618. <https://doi.org/10.1074/mcp.RA119.001506>.
- (33) Arun, A.; Ansari, M. I.; Popli, P.; Jaiswal, S.; Mishra, A. K.; Dwivedi, A.; Hajela, K.; Konwar, R. New Piperidine Derivative DTPEP Acts as Dual-Acting Anti-Breast Cancer Agent by Targeting ER α and Downregulating PI3K/Akt-PKC α Leading to Caspase-Dependent Apoptosis. *Cell Prolif* **2018**, *51* (6), e12501. <https://doi.org/https://doi.org/10.1111/cpr.12501>.
- (34) Han, R.; Gu, S.; Zhang, Y.; Luo, A.; Jing, X.; Zhao, L.; Zhao, X.; Zhang, L. Estrogen Promotes Progression of Hormone-Dependent Breast Cancer through CCL2-CCR2 Axis by Upregulation of Twist via PI3K/AKT/NF-KB Signaling. *Sci Rep* **2018**, *8* (1), 9575. <https://doi.org/10.1038/s41598-018-27810-6>.
- (35) Liu, Y.; Ma, H.; Yao, J. ER α , a Key Target for Cancer Therapy: A Review. *OncoTargets and Therapy*. Dove Medical Press Ltd. 2020, pp 2183–2191. <https://doi.org/10.2147/OTT.S236532>.
- (36) Beato, M.; Sánchez-Pacheco, A. Interaction of Steroid Hormone Receptors with the Transcription Initiation Complex. *Endocr Rev* **1996**, *17* (6), 587–609. <https://doi.org/10.1210/edrv-17-6-587>.
- (37) Pedram, A.; Razandi, M.; Sainson, R. C. A.; Kim, J. K.; Hughes, C. C.; Levin, E. R. A Conserved Mechanism for Steroid Receptor Translocation to the Plasma Membrane *. *Journal of Biological Chemistry* **2007**, *282* (31), 22278–22288. <https://doi.org/10.1074/jbc.M611877200>.
- (38) Dohlman, H. G. Thematic Minireview Series: Cell Biology of G Protein Signaling. *Journal of Biological Chemistry* **2015**, *290* (11), 6679–6680. <https://doi.org/10.1074/jbc.R114.631093>.
- (39) Aronica, S. M.; Kraus, W. L.; Katzenellenbogen, B. S. Estrogen Action via the CAMP Signaling Pathway: Stimulation of Adenylate Cyclase and CAMP-Regulated Gene Transcription. *Proceedings of the National Academy of Sciences* **1994**, *91* (18), 8517–8521. <https://doi.org/10.1073/pnas.91.18.8517>.
- (40) Chambliss, K. L.; Wu, Q.; Oltmann, S.; Konaniah, E. S.; Umetani, M.; Korach, K. S.; Thomas, G. D.; Mineo, C.; Yuhanna, I. S.; Kim, S. H.; Madak-Erdogan, Z.;

- Maggi, A.; Dineen, S. P.; Roland, C. L.; Hui, D. Y.; Brekken, R. A.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S.; Shaul, P. W. Non-Nuclear Estrogen Receptor α Signaling Promotes Cardiovascular Protection but Not Uterine or Breast Cancer Growth in Mice. *J Clin Invest* **2010**, *120* (7), 2319–2330. <https://doi.org/10.1172/JCI38291>.
- (41) Divekar, S. D.; Storchan, G. B.; Sperle, K.; Veselik, D. J.; Johnson, E.; Dakshanamurthy, S.; Lajiminmuhip, Y. N.; Nakles, R. E.; Huang, L.; Martin, M. B. The Role of Calcium in the Activation of Estrogen Receptor-Alpha. *Cancer Res* **2011**, *71* (5), 1658–1668. <https://doi.org/10.1158/0008-5472.CAN-10-1899>.
- (42) Piperigkou, Z.; Karamanos, N. K. Estrogen Receptor-Mediated Targeting of the Extracellular Matrix Network in Cancer. *Semin Cancer Biol* **2020**, *62*, 116–124. <https://doi.org/https://doi.org/10.1016/j.semcancer.2019.07.006>.
- (43) Márquez, D. C.; Chen, H.-W.; Curran, E. M.; Welshons, W. V.; Pietras, R. J. Estrogen Receptors in Membrane Lipid Rafts and Signal Transduction in Breast Cancer. *Mol Cell Endocrinol* **2006**, *246* (1), 91–100. <https://doi.org/https://doi.org/10.1016/j.mce.2005.11.020>.
- (44) Becker, M. A.; Ibrahim, Y. H.; Cui, X.; Lee, A. V.; Yee, D. The IGF Pathway Regulates ER α through a S6K1-Dependent Mechanism in Breast Cancer Cells. *Molecular Endocrinology* **2011**, *25* (3), 516–528. <https://doi.org/10.1210/me.2010-0373>.
- (45) Gelbert, L. M.; Cai, S.; Lin, X.; Sanchez-Martinez, C.; Prado, M. Del; Lallena, M. J.; Torres, R.; Ajamie, R. T.; Wishart, G. N.; Flack, R. S.; Neubauer, B. L.; Young, J.; Chan, E. M.; Iversen, P.; Cronier, D.; Kreklau, E.; De Dios, A. Preclinical Characterization of the CDK4/6 Inhibitor LY2835219: In-Vivo Cell Cycle-Dependent/Independent Anti-Tumor Activities Alone/in Combination with Gemcitabine. *Invest New Drugs* **2014**, *32* (5), 825–837. <https://doi.org/10.1007/s10637-014-0120-7>.
- (46) *CDK4 cyclin dependent kinase 4 [Homo sapiens (human)]*. NCBI. <https://www.ncbi.nlm.nih.gov/gene/1019> (accessed 2024-07-12).
- (47) *CDK6 cyclin dependent kinase 6 [Homo sapiens (human)]*. NCBI. <https://www.ncbi.nlm.nih.gov/gene/1021> (accessed 2024-07-12).
- (48) Thill, M.; Schmidt, M. Management of Adverse Events during Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitor-Based Treatment in Breast Cancer. *Ther Adv Med Oncol* **2018**, *10*, 1758835918793326. <https://doi.org/10.1177/1758835918793326>.
- (49) Wekking, D.; Leoni, V. P.; Lambertini, M.; Dessi, M.; Pretta, A.; Cadoni, A.; Atzori, L.; Scartozzi, M.; Solinas, C. CDK4/6 Inhibition in Hormone Receptor-Positive/HER2-Negative Breast Cancer: Biological and Clinical Aspects. *Cytokine and Growth Factor Reviews*. Elsevier Ltd 2023. <https://doi.org/10.1016/j.cytogfr.2023.10.001>.
- (50) Goel, S.; Bergholz, J. S.; Zhao, J. J. Targeting CDK4 and CDK6 in Cancer. *Nat Rev Cancer* **2022**, *22* (6), 356–372. <https://doi.org/10.1038/s41568-022-00456-3>.
- (51) *CDK2 cyclin dependent kinase 2 [Homo sapiens (human)]*. NCBI. <https://www.ncbi.nlm.nih.gov/gene/1017> (accessed 2024-07-12).
- (52) Tadesse, S.; Anshabo, A. T.; Portman, N.; Lim, E.; Tilley, W.; Caldon, C. E.; Wang, S. Targeting CDK2 in Cancer: Challenges and Opportunities for Therapy. *Drug Discovery Today*. Elsevier Ltd February 1, 2020, pp 406–413. <https://doi.org/10.1016/j.drudis.2019.12.001>.
- (53) Papadimitriou, M. C.; Pazaiti, A.; Iliakopoulos, K.; Markouli, M.; Michalaki, V.; Papadimitriou, C. A. Resistance to CDK4/6 Inhibition: Mechanisms and Strategies to Overcome a Therapeutic Problem in the Treatment of Hormone

- Receptor-Positive Metastatic Breast Cancer. *Biochimica et Biophysica Acta - Molecular Cell Research*. Elsevier B.V. December 1, 2022. <https://doi.org/10.1016/j.bbamcr.2022.119346>.
- (54) Zardavas, D.; Pondé, N.; Tryfonidis, K. CDK4/6 Blockade in Breast Cancer: Current Experience and Future Perspectives. *Expert Opin Investig Drugs* **2017**, *26* (12), 1357–1372. <https://doi.org/10.1080/13543784.2017.1389896>.
- (55) Jorda, R.; Bučková, Z.; Řezníčková, E.; Bouchal, J.; Kryštof, V. Selective Inhibition Reveals Cyclin-Dependent Kinase 2 as Another Kinase That Phosphorylates the Androgen Receptor at Serine 81. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research* **2018**, *1865* (2), 354–363. <https://doi.org/https://doi.org/10.1016/j.bbamcr.2017.11.011>.
- (56) Rogatsky, I.; Trowbridge, J. M.; Garabedian, M. J. Potentiation of Human Estrogen Receptor α Transcriptional Activation through Phosphorylation of Serines 104 and 106 by the Cyclin A-CDK2 Complex*. *Journal of Biological Chemistry* **1999**, *274* (32), 22296–22302. <https://doi.org/https://doi.org/10.1074/jbc.274.32.22296>.
- (57) Pierson-Mullany, L. K.; Lange, C. A. Phosphorylation of Progesterone Receptor Serine 400 Mediates Ligand-Independent Transcriptional Activity in Response to Activation of Cyclin-Dependent Protein Kinase 2. *Mol Cell Biol* **2004**, *24* (24), 10542–10557. <https://doi.org/10.1128/mcb.24.24.10542-10557.2004>.
- (58) Knudsen, E. S.; Witkiewicz, A. K. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. *Trends Cancer* **2017**, *3* (1), 39–55. <https://doi.org/https://doi.org/10.1016/j.trecan.2016.11.006>.
- (59) Herrera-Abreu, M. T.; Palafox, M.; Asghar, U.; Rivas, M. A.; Cutts, R. J.; Garcia-Murillas, I.; Pearson, A.; Guzman, M.; Rodriguez, O.; Gueso, J.; Bellet, M.; Cortés, J.; Elliott, R.; Pancholi, S.; Lord, C. J.; Baselga, J.; Dowsett, M.; Martin, L.-A.; Turner, N. C.; Serra, V. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer. *Cancer Res* **2016**, *76* (8), 2301–2313. <https://doi.org/10.1158/0008-5472.CAN-15-0728>.
- (60) Patel, P.; Tshiperson, V.; Gottesman, S. R. S.; Somma, J.; Blain, S. W. Dual Inhibition of CDK4 and CDK2 via Targeting P27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells. *Molecular Cancer Research* **2018**, *16* (3), 361–377. <https://doi.org/10.1158/1541-7786.MCR-17-0602>.
- (61) Kutuk, O.; Letai, A. *Regulation of Bcl-2 Family Proteins by Posttranslational Modifications*; 2008; Vol. 8.
- (62) *BCL2L1 BCL2 like 1 [Homo sapiens (human)]*. NCBI. <https://www.ncbi.nlm.nih.gov/gene/598> (accessed 2024-07-12).
- (63) Shamas-Din, A.; Brahmabhatt, H.; Leber, B.; Andrews, D. W. BH3-Only Proteins: Orchestrators of Apoptosis. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research* **2011**, *1813* (4), 508–520. <https://doi.org/https://doi.org/10.1016/j.bbamcr.2010.11.024>.
- (64) Lomonosova, E.; Chinnadurai, G. BH3-Only Proteins in Apoptosis and beyond: An Overview. *Oncogene* **2008**, *27* (1), S2–S19. <https://doi.org/10.1038/onc.2009.39>.
- (65) Kawiak, A.; Kostecka, A. Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy. *Cancers*. MDPI January 1, 2022. <https://doi.org/10.3390/cancers14020279>.
- (66) Kim, H.-E.; Du, F.; Fang, M.; Wang, X. Formation of Apoptosome Is Initiated by Cytochrome C-Induced DATP Hydrolysis and Subsequent Nucleotide Exchange on Apaf-1. *Proceedings of the National Academy of Sciences* **2005**, *102* (49), 17545–17550. <https://doi.org/10.1073/pnas.0507900102>.

- (67) Wang, Y. H.; Morris-Natschke, S.; Yang, J.; Niu, H. M.; Long, C. L.; Lee, K. H. Anticancer Principles from Medicinal Piper (Hú Jiāo) Plants. *J Tradit Complement Med* **2014**, *4* (1), 8–16. <https://doi.org/10.4103/2225-4110.124811>.
- (68) Mgbeahuruike, E. E.; Yrjönen, T.; Vuorela, H.; Holm, Y. Bioactive Compounds from Medicinal Plants: Focus on Piper Species. *South African Journal of Botany* **2017**, *112*, 54–69. <https://doi.org/https://doi.org/10.1016/j.sajb.2017.05.007>.
- (69) Parmar, V. S.; Jain, S. C.; Bisht, K. S.; Jain, R.; Taneja, P.; Jha, A.; Tyagi, O. D.; Prasad, A. K.; Wengel, J.; Olsen, C. E.; Boll, P. M. Phytochemistry of the Genus Piper. *Phytochemistry* **1997**, *46* (4), 597–673. [https://doi.org/https://doi.org/10.1016/S0031-9422\(97\)00328-2](https://doi.org/https://doi.org/10.1016/S0031-9422(97)00328-2).
- (70) Jensen, S.; Hansen, J.; Boll, P. M. Lignans and Neolignans from Piperaceae. *Phytochemistry* **1993**, *33* (3), 523–530. [https://doi.org/https://doi.org/10.1016/0031-9422\(93\)85442-T](https://doi.org/https://doi.org/10.1016/0031-9422(93)85442-T).
- (71) Zálešák, F.; Bon, D. J.-Y. D.; Pospíšil, J. Lignans and Neolignans: Plant Secondary Metabolites as a Reservoir of Biologically Active Substances. *Pharmacol Res* **2019**, *146*, 104284. <https://doi.org/https://doi.org/10.1016/j.phrs.2019.104284>.
- (72) Alonso-Castro, A. J.; Villarreal, M. L.; Salazar-Olivo, L. A.; Gomez-Sanchez, M.; Dominguez, F.; Garcia-Carranca, A. Mexican Medicinal Plants Used for Cancer Treatment: Pharmacological, Phytochemical and Ethnobotanical Studies. *J Ethnopharmacol* **2011**, *133* (3), 945–972. <https://doi.org/https://doi.org/10.1016/j.jep.2010.11.055>.
- (73) Parmar, V. S.; Jain, S. C.; Bisht, K. S.; Jain, R.; Taneja, P.; Jha, A.; Tyagi, O. D.; Prasad, A. K.; Wengel, J.; Olsen, C. E.; Boll, P. M. *PHYTOCHEMISTRY OF THE GENUS PIPER ZyxwvutsrqponmlkjihgfedcbaZ*; 1997; Vol. 46.
- (74) Walle, T. Methoxylated Flavones, a Superior Cancer Chemopreventive Flavonoid Subclass? *Semin Cancer Biol* **2007**, *17* (5), 354–362. <https://doi.org/https://doi.org/10.1016/j.semcancer.2007.05.002>.
- (75) Herkenne, C.; Alberti, I.; Naik, A.; Kalia, Y. N.; Mathy, F.-X.; Prétat, V.; Guy, R. H. In Vivo Methods for the Assessment of Topical Drug Bioavailability. *Pharm Res* **2008**, *25* (1), 87–103. <https://doi.org/10.1007/s11095-007-9429-7>.
- (76) Olivares-Morales, A.; Hatley, O. J. D.; Turner, D.; Galetin, A.; Aarons, L.; Rostami-Hodjegan, A. The Use of ROC Analysis for the Qualitative Prediction of Human Oral Bioavailability from Animal Data. *Pharm Res* **2014**, *31* (3), 720–730. <https://doi.org/10.1007/s11095-013-1193-2>.
- (77) Petit, J.; Meurice, N.; Kaiser, C.; Maggiora, G. Softening the Rule of Five—Where to Draw the Line? *Bioorg Med Chem* **2012**, *20* (18), 5343–5351. <https://doi.org/https://doi.org/10.1016/j.bmc.2011.11.064>.
- (78) Lipinski, C. A. Rule of Five in 2015 and beyond: Target and Ligand Structural Limitations, Ligand Chemistry Structure and Drug Discovery Project Decisions. *Adv Drug Deliv Rev* **2016**, *101*, 34–41. <https://doi.org/https://doi.org/10.1016/j.addr.2016.04.029>.
- (79) Chen, X.; Li, H.; Tian, L.; Li, Q.; Luo, J.; Zhang, Y. Analysis of the Physicochemical Properties of Acaricides Based on Lipinski's Rule of Five. *Journal of Computational Biology* **2020**, *27* (9), 1397–1406. <https://doi.org/10.1089/cmb.2019.0323>.
- (80) Kapetanovic, I. M. Computer-Aided Drug Discovery and Development (CADD): In Silico-Chemico-Biological Approach. *Chem Biol Interact* **2008**, *171* (2), 165–176. <https://doi.org/https://doi.org/10.1016/j.cbi.2006.12.006>.
- (81) Jain, A. N.; Nicholls, A. Recommendations for Evaluation of Computational Methods. *J Comput Aided Mol Des* **2008**, *22* (3), 133–139. <https://doi.org/10.1007/s10822-008-9196-5>.

- (82) Meng, X.-Y.; Zhang, H.-X.; Mezei, M.; Cui, M. *Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery*.
- (83) Agarwal, S.; Mehrotra, R. An Overview of Molecular Docking. *JSM Chem* **2016**, *4* (2), 1024.
- (84) Venhorst, J.; ter Laak, A. M.; Commandeur, J. N. M.; Funae, Y.; Hiroi, T.; Vermeulen, N. P. E. Homology Modeling of Rat and Human Cytochrome P450 2D (CYP2D) Isoforms and Computational Rationalization of Experimental Ligand-Binding Specificities. *J Med Chem* **2003**, *46* (1), 74–86. <https://doi.org/10.1021/jm0209578>.
- (85) Agu, P. C.; Afiukwa, C. A.; Orji, O. U.; Ezech, E. M.; Ofoke, I. H.; Ogbu, C. O.; Ugwuja, E. I.; Aja, P. M. Molecular Docking as a Tool for the Discovery of Molecular Targets of Nutraceuticals in Diseases Management. *Sci Rep* **2023**, *13* (1). <https://doi.org/10.1038/s41598-023-40160-2>.
- (86) Raval, K.; Ganatra, T. Basics, Types and Applications of Molecular Docking: A Review. *IP International Journal of Comprehensive and Advanced Pharmacology* **2022**, *7* (1), 12–16. <https://doi.org/10.18231/j.ijcaap.2022.003>.
- (87) Clark, A. M.; Labute, P. 2D Depiction of Protein–Ligand Complexes. *J Chem Inf Model* **2007**, *47* (5), 1933–1944. <https://doi.org/10.1021/ci7001473>.
- (88) Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. *J Comput Chem* **2009**, *30* (16), 2785–2791. <https://doi.org/https://doi.org/10.1002/jcc.21256>.
- (89) Jia, C.-Y.; Li, J.-Y.; Hao, G.-F.; Yang, G.-F. A Drug-Likeness Toolbox Facilitates ADMET Study in Drug Discovery. *Drug Discov Today* **2020**, *25* (1), 248–258. <https://doi.org/https://doi.org/10.1016/j.drudis.2019.10.014>.
- (90) Lipinski, C. A. Lead- and Drug-like Compounds: The Rule-of-Five Revolution. *Drug Discov Today Technol* **2004**, *1* (4), 337–341. <https://doi.org/https://doi.org/10.1016/j.ddtec.2004.11.007>.
- (91) Delmas, P. D.; Ensrud, K. E.; Adachi, J. D.; Harper, K. D.; Sarkar, S.; Gennari, C.; Reginster, J.-Y.; Pols, H. A. P.; Recker, R. R.; Harris, S. T.; Wu, W.; Genant, H. K.; Black, D. M.; Eastell, R. Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial. *J Clin Endocrinol Metab* **2002**, *87* (8), 3609–3617. <https://doi.org/10.1210/jcem.87.8.8750>.
- (92) C, T. N.; Jungsil, R.; Fabrice, A.; Sherene, L.; Sunil, V.; Hiroji, I.; Nadia, H.; Sibylle, L.; Cynthia, H. B.; Ke, Z.; Carla, G.; Sophia, R.; Maria, K.; Massimo, C. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. *New England Journal of Medicine* **2024**, *373* (3), 209–219. <https://doi.org/10.1056/NEJMoa1505270>.
- (93) Khalil, H. S.; Mitev, V.; Vlaykova, T.; Cavicchi, L.; Zhelev, N. Discovery and Development of Seliciclib. How Systems Biology Approaches Can Lead to Better Drug Performance. *J Biotechnol* **2015**, *202*, 40–49. <https://doi.org/https://doi.org/10.1016/j.jbiotec.2015.02.032>.
- (94) Mohamad Anuar, N. N.; Nor Hisam, N. S.; Liew, S. L.; Ugusman, A. Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent. *Frontiers in Pharmacology*. Frontiers Media S.A. November 26, 2020. <https://doi.org/10.3389/fphar.2020.564108>.
- (95) Buxton, I. L. O. Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and Elimination. In *Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e*; Brunton, L. L., Hilal-Dandan, R., Knollmann, B. C., Eds.; McGraw-Hill Education: New York, NY, 2017.

- (96) Sharma, M.; Sharma, N.; Saxena, G.; Akhtar, S. *INSIGHTING INTERACTION PATTERNS IN 7-ACETYLBHORMINONE VIA DOCKING STUDIES AGAINST CDK2 AS ANTICANCER THERAPEUTIC TARGET*. <https://www.cgl.ucsf.edu/chimera/download.html>.
- (97) Bhojwani, H. R.; Joshi, U. J. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase. *Curr Comput Aided Drug Des* **2017**, *13* (3). <https://doi.org/10.2174/1386207319666161214112536>.
- (98) Shivanika, C.; Deepak Kumar, S.; Ragunathan, V.; Tiwari, P.; Sumitha, A.; Brindha Devi, P. Molecular Docking, Validation, Dynamics Simulations, and Pharmacokinetic Prediction of Natural Compounds against the SARS-CoV-2 Main-Protease. *J Biomol Struct Dyn* **2022**, *40* (2), 585–611. <https://doi.org/10.1080/07391102.2020.1815584>.
- (99) John, M.; Pintacuda, G.; Park, A. Y.; Dixon, N. E.; Otting, G. Structure Determination of Protein–Ligand Complexes by Transferred Paramagnetic Shifts. *J Am Chem Soc* **2006**, *128* (39), 12910–12916. <https://doi.org/10.1021/ja063584z>.
- (100) Guedes, I. A.; de Magalhães, C. S.; Dardenne, L. E. Receptor-Ligand Molecular Docking. *Biophysical Reviews*. March 2014, pp 75–87. <https://doi.org/10.1007/s12551-013-0130-2>.
- (101) Alamri, A.; Rauf, A.; Khalil, A. A.; Alghamdi, A.; Alafnan, A.; Alshammari, A.; Alshammari, F.; Malik, J. A.; Anwar, S. In Silico Screening of Marine Compounds as an Emerging and Promising Approach against Estrogen Receptor Alpha-Positive Breast Cancer. *Biomed Res Int* **2021**, 2021. <https://doi.org/10.1155/2021/9734279>.
- (102) Yousif, F. A.; Alzain, A. A.; Alraih, A. M.; Ibraheem, W. Repurposing of Approved Drugs for Targeting CDK4/6 and Aromatase Protein Using Molecular Docking and Molecular Dynamics Studies. *PLoS One* **2023**, *18* (9 September). <https://doi.org/10.1371/journal.pone.0291256>.
- (103) Chiou, J.-T.; Lee, Y.-C.; Wang, L.-J.; Chang, L.-S. BCL2 Inhibitor ABT-199 and BCL2L1 Inhibitor WEHI-539 Coordinately Promote NOXA-Mediated Degradation of MCL1 in Human Leukemia Cells. *Chem Biol Interact* **2022**, *361*, 109978. <https://doi.org/https://doi.org/10.1016/j.cbi.2022.109978>.

